Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Repealing the Job-Killing Health Care Law Act
Client: AMERICA'S SPECIALTY MEDICINE COMPANIES (COMPRISED OF PARTICIPANTS ON LINE 13) · Firm: CONSTANTINE CANNON, LLP
S. 319 -- drug reimportation PDUFA reauthorization H.R.2632, S.1410 -- Life Sciences Jobs and Investment Act Orphan drugs H.R.2672, S.1423 -- Preserving Access to Orphan Drugs Act of 2011 H.R. 2 -- healthcare reform bill repeal Medicare rebates and reimbursement rates 340B drug discount program H.R.2674 -- 340B Program Improvement Act
Repealing the Job-Killing Health Care Law Act
Client: AMERICA'S SPECIALTY MEDICINE COMPANIES (COMPRISED OF PARTICIPANTS ON LINE 13) · Firm: CONSTANTINE CANNON, LLP
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
AMERICA'S SPECIALTY MEDICINE COMPANIES (COMPRISED OF PARTICIPANTS ON LINE 13) via CONSTANTINE CANNON, LLP
2011 · fourth_quarter · Q4
S. 319 -- drug reimportation PDUFA reauthorization H.R.2632, S.1410 -- Life Sciences Jobs and Investment Act Orphan drugs H.R.2672, S.1423 -- Preserving Access to Orphan Drugs Act of 2011 H.R. 2 -- healthcare reform bill repeal Medicare rebates and reimbursement rates 340B drug discount program H.R.2674 -- 340B Program Improvement Act
S. 27 -- patent settlements H.R. 1249, S. 23 -- patent reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
S. 319 -- drug reimportation PDUFA reauthorization H.R.2632, S.1410 -- Life Sciences Jobs and Investment Act Orphan drugs H.R.2672, S.1423 -- Preserving Access to Orphan Drugs Act of 2011 H.R. 2 -- healthcare reform bill repeal Medicare rebates and reimbursement rates 340B drug discount program H.R.2674 -- 340B Program Improvement Act
Life Sciences Jobs and Investment Act of 2011
Client: AMERICA'S SPECIALTY MEDICINE COMPANIES (COMPRISED OF PARTICIPANTS ON LINE 13) · Firm: CONSTANTINE CANNON, LLP
S. 319 -- drug reimportation PDUFA reauthorization H.R.2632, S.1410 -- Life Sciences Jobs and Investment Act Orphan drugs H.R.2672, S.1423 -- Preserving Access to Orphan Drugs Act of 2011 H.R. 2 -- healthcare reform bill repeal Medicare rebates and reimbursement rates 340B drug discount program H.R.2674 -- 340B Program Improvement Act
Life Sciences Jobs and Investment Act of 2011
Client: AMERICA'S SPECIALTY MEDICINE COMPANIES (COMPRISED OF PARTICIPANTS ON LINE 13) · Firm: CONSTANTINE CANNON, LLP
S. 319 -- drug reimportation PDUFA reauthorization H.R.2632, S.1410 -- Life Sciences Jobs and Investment Act Orphan drugs H.R.2672, S.1423 -- Preserving Access to Orphan Drugs Act of 2011 H.R. 2 -- healthcare reform bill repeal Medicare rebates and reimbursement rates 340B drug discount program H.R.2674 -- 340B Program Improvement Act
Preserving Access to Orphan Drugs Act of 2011
Client: AMERICA'S SPECIALTY MEDICINE COMPANIES (COMPRISED OF PARTICIPANTS ON LINE 13) · Firm: CONSTANTINE CANNON, LLP
S. 319 -- drug reimportation PDUFA reauthorization H.R.2632, S.1410 -- Life Sciences Jobs and Investment Act Orphan drugs H.R.2672, S.1423 -- Preserving Access to Orphan Drugs Act of 2011 H.R. 2 -- healthcare reform bill repeal Medicare rebates and reimbursement rates 340B drug discount program H.R.2674 -- 340B Program Improvement Act
Preserving Access to Orphan Drugs Act of 2011
Client: AMERICA'S SPECIALTY MEDICINE COMPANIES (COMPRISED OF PARTICIPANTS ON LINE 13) · Firm: CONSTANTINE CANNON, LLP
S. 319 -- drug reimportation PDUFA reauthorization H.R.2632, S.1410 -- Life Sciences Jobs and Investment Act Orphan drugs H.R.2672, S.1423 -- Preserving Access to Orphan Drugs Act of 2011 H.R. 2 -- healthcare reform bill repeal Medicare rebates and reimbursement rates 340B drug discount program H.R.2674 -- 340B Program Improvement Act
340B Program Improvement Act
Client: AMERICA'S SPECIALTY MEDICINE COMPANIES (COMPRISED OF PARTICIPANTS ON LINE 13) · Firm: CONSTANTINE CANNON, LLP
S. 319 -- drug reimportation PDUFA reauthorization H.R.2632, S.1410 -- Life Sciences Jobs and Investment Act Orphan drugs H.R.2672, S.1423 -- Preserving Access to Orphan Drugs Act of 2011 H.R. 2 -- healthcare reform bill repeal Medicare rebates and reimbursement rates 340B drug discount program H.R.2674 -- 340B Program Improvement Act
340B Program Improvement Act
Client: AMERICA'S SPECIALTY MEDICINE COMPANIES (COMPRISED OF PARTICIPANTS ON LINE 13) · Firm: CONSTANTINE CANNON, LLP
S. 319 -- drug reimportation PDUFA reauthorization H.R.2632, S.1410 -- Life Sciences Jobs and Investment Act Orphan drugs H.R.2672, S.1423 -- Preserving Access to Orphan Drugs Act of 2011 H.R. 2 -- healthcare reform bill repeal Medicare rebates and reimbursement rates 340B drug discount program H.R.2674 -- 340B Program Improvement Act
AMERICA'S SPECIALTY MEDICINE COMPANIES (COMPRISED OF PARTICIPANTS ON LINE 13) via CONSTANTINE CANNON, LLP
2011 · third_quarter · Q3
S. 319 -- drug reimportation PDUFA reauthorization H.R.2632, S.1410 -- Life Sciences Jobs and Investment Act Orphan drugs H.R.2672, S.1423 -- Preserving Access to Orphan Drugs Act of 2011 H.R. 2 -- healthcare reform bill repeal Medicare rebates and reimbursement rates 340B drug discount program H.R.2674 -- 340B Program Improvement Act
S. 27 -- patent settlements H.R. 1249, S. 23 -- patent reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE